[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369354-105":59,"doc-detail-369354-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","lig1-is-a-synthetic-lethal-target-in-brca1-mutant-cancers","LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers","","BRCA1 inactivation drives substantial inherited susceptibility to breast and ovarian cancers, and PARP inhibitors provide clinical evidence for synthetic lethality. Synthetic lethality relies on interactions where disruption of either gene alone supports viability, while combined perturbation causes cell death. PARP enzymes participate in DNA repair pathways, and in homologous recombination deficiency contexts they promote lethal replication stress. This study uses CRISPR/Cas9-based screening and multiple validation approaches to assess DNA ligase I (LIG1) as a synthetic lethal target in BRCA1-mutant cancers, linking LIG1 loss to selective viability impairment, mechanistic PAR signaling changes, and in vivo tumor stasis. ",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lig1-is-a-synthetic-lethal-target-in-brca1-mutant-cancers/369354/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lig1-is-a-synthetic-lethal-target-in-brca1-mutant-cancers/369354.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main rationale for using synthetic lethality in BRCA1-mutant cancers?","Question",{"text":113,"@type":114},"Synthetic lethality describes gene interactions where either single-gene disruption is compatible with viability, but combined perturbation produces lethality. In BRCA1-related homologous recombination deficiency, PARP inhibition increases DNA damage and replication stress leading to cell death.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did the study identify LIG1 as a synthetic lethal target?",{"text":118,"@type":114},"CRISPR/Cas9-based screening was used to pinpoint DNA ligase I (LIG1) as a novel synthetic lethal target in BRCA1-mutated cancers, followed by confirmation with CRISPRn, CRISPRi, RNAi, and protein degradation.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence demonstrates that LIG1 targeting is selective for the BRCA1 mutant context?",{"text":122,"@type":114},"LIG1 inactivation caused viability loss across multiple BRCA1-mutant cell lines, while no effect was observed in BRCA1/2 wild-type cell lines. Additional rescue experiments with exogenous wild-type LIG1 cDNA supported an on-target phenotype.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369354,1790196856,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers  \nLauren Catherine M. Martires, Leanne G. Ahronian, Charlotte B. Pratt, Nikitha M. Das, Xiaobin Zhang, Douglas A. Whittington, Hongxiang Zhang, Binzhang Shen, Jon Come, Patrick McCarren, Mu-Sen Liu, Chengyin Min, Tianshu Feng, Haris Jahic, Janid A. Ali, Daniel R. Aird, Fang Li, Jannik N. Andersen, Alan Huang, William D. Mallender, and Hilary E. Nicholson  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Synthetic lethality approaches in BRCA1/2-mutated cancers have focused on PARP inhibitors, which are subject to high rates of innate or acquired resistance in patients. In this study, we used CRISPR/Cas9-based screening to identify DNA ligase I (LIG1) asa novel target for synthetic lethality in BRCA1-mutated cancers.\u003Cbr>Publicly available data supported LIG1 hyperdependence of BRCA1 mutant cells across a variety of breast and ovarian cancer cell lines. We used CRISPRn, CRISPRi, RNAi, and protein degradation to confirm the lethal effect of LIG1 inactivation at the DNA, RNA, and protein level in BRCA1 mutant cells in vitro. LIG1 inactivation resulted in viability loss across multiple BRCA1-mutated cell lines, whereas no effect was observed in BRCA1/2 wild-type cell lines, demonstrating target selectivity for the BRCA1 mutant context. On-target nature of the phenotype\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | was demonstrated through rescue of viability with exogenous wild-type LIG1 cDNA. Next, we demonstrated a concentrationdependent relationship of LIG1 protein expression and BRCA1 mutant cell viability using a titratable, degradable LIG1 fusion protein. BRCA1 mutant viability required LIG1 catalytic activity, as catalytically dead mutant LIG1K568A failed to rescue viability loss caused by endogenous LIG1 depletion. LIG1 perturbation produced proportional increases in PAR staining in BRCA1 mutant cells, indicating a mechanism consistent with the function of LIG1 in sealing ssDNA nicks. Finally, we confirmed LIG1 hyperdependence in vivo using a xenograft model in which LIG1 loss resulted in tumor stasis in all mice. Our cumulative findings demonstrate that LIG1 is a promising synthetic lethal target for development in patients with BRCA1-mutant cancers. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nInactivation of the BRCA1 gene is responsible for a large percentage of inherited predispositions to breast and ovarian cancers in women, with associated lifetime risk estimates of 80% and 40% to 65%, respectively (1) . Loss or mutation of BRCA1 has also been associated with colon and prostate cancers in men (2) . In December 2014, the FDA approved the first PARP inhibitor for patients with BRCA1/2-mutated ovarian cancer, providing clinical proof-ofconcept for synthetic lethality as an anticancer strategy. Synthetic lethality describes a gene interaction in which mutation or disruption of one of the int","cbCainPEbxIEXuAl","https://ap.wps.com/l/cbCainPEbxIEXuAl","pdf",8759231,"English","# Introduction\n## BRCA1 and cancer risk\n## Synthetic lethality concept\n## DNA repair and PARP inhibition\n## Rationale for identifying LIG1","[{\"question\":\"What is the main rationale for using synthetic lethality in BRCA1-mutant cancers?\",\"answer\":\"Synthetic lethality describes gene interactions where either single-gene disruption is compatible with viability, but combined perturbation produces lethality. In BRCA1-related homologous recombination deficiency, PARP inhibition increases DNA damage and replication stress leading to cell death.\"},{\"question\":\"How did the study identify LIG1 as a synthetic lethal target?\",\"answer\":\"CRISPR/Cas9-based screening was used to pinpoint DNA ligase I (LIG1) as a novel synthetic lethal target in BRCA1-mutated cancers, followed by confirmation with CRISPRn, CRISPRi, RNAi, and protein degradation.\"},{\"question\":\"What evidence demonstrates that LIG1 targeting is selective for the BRCA1 mutant context?\",\"answer\":\"LIG1 inactivation caused viability loss across multiple BRCA1-mutant cell lines, while no effect was observed in BRCA1/2 wild-type cell lines. Additional rescue experiments with exogenous wild-type LIG1 cDNA supported an on-target phenotype.\"}]","LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers | PDF",1790182211,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f1d72e42098f5905191681a7de02739.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba4b2e77235ca273598c8cd69a098c27.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d344f48b3c98caea335f9a2bd59ac1b.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f33d04108ef7351b1fe0dd7921e3078a.webp",980,1311]